Literature DB >> 30299237

Cumulative Radiation Exposures from CT Screening and Surveillance Strategies for von Hippel-Lindau-associated Solid Pancreatic Tumors.

Amit Tirosh1, Neige Journy1, Les R Folio1, Choonsik Lee1, Christiane Leite1, Jianhua Yao1, William Kovacs1, W Marston Linehan1, Ashkan Malayeri1, Electron Kebebew1, Amy Berrington de González1.   

Abstract

Purpose To assess the potential ionizing radiation exposure from CT scans for both screening and surveillance of patients with von Hippel-Lindau (VHL) syndrome. Materials and Methods For this retrospective study, abdomen-pelvic (AP) and chest-abdomen-pelvic (CAP) CT scans were performed with either a three-phase (n = 1242) or a dual-energy virtual noncontrast protocol (VNC; n = 149) in 747 patients with VHL syndrome in the National Institutes of Health Clinical Center between 2009 and 2015 (mean age, 47.6 years ± 14.6 [standard deviation]; age range, 12-83 years; 320 women [42.8%]). CT scanning parameters for patients with pancreatic neuroendocrine tumors (PNETs; 124 patients and 381 scans) were compared between a tumor diameter-based surveillance protocol and a VHL genotype and tumor diameter-based algorithm (a tailored algorithm) developed by three VHL clinicians. Organ and lifetime radiation doses were estimated by two radiologists and five radiation scientists. Cumulative radiation doses were compared between the PNET surveillance algorithms by analyses of variance, and a two-tailed P value less than .05 indicated statistical significance. Results Median cumulative colon doses for annual CAP and AP CT scans from age 15 to 40 years ranged from 0.34 Gy (5th-95th percentiles, 0.18-0.75; dual-energy VNC CT) to 0.89 Gy (5th-95th percentiles, 0.42-1.0; three-phase CT). For the current PNET surveillance protocol, the cumulative effective radiation dose from age 40 to 65 years was 682 mSv (tumors < 1.2 cm) and 2125 mSv (tumors > 3 cm). The tailored algorithm could halve these doses for patients with initial tumor diameter less than 1.2 cm (P < .001). Conclusion CT screening of patients with von Hippel-Lindau syndrome can lead to substantial radiation exposures, even with dual-energy virtual noncontrast CT. A genome and tumor diameter-based algorithm for pancreatic neuroendocrine tumor surveillance may potentially reduce lifetime radiation exposure. © RSNA, 2018 Online supplemental material is available for this article.

Entities:  

Mesh:

Year:  2018        PMID: 30299237      PMCID: PMC6312431          DOI: 10.1148/radiol.2018180687

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  30 in total

1.  Survival and causes of death in patients with von Hippel-Lindau disease.

Authors:  Marie Louise Mølgaard Binderup; Annette Møller Jensen; Esben Budtz-Jørgensen; Marie Luise Bisgaard
Journal:  J Med Genet       Date:  2016-08-18       Impact factor: 6.318

Review 2.  Dual energy CT applications in pancreatic pathologies.

Authors:  Elizabeth George; Jeremy R Wortman; Urvi P Fulwadhva; Jennifer W Uyeda; Aaron D Sodickson
Journal:  Br J Radiol       Date:  2017-09-22       Impact factor: 3.039

Review 3.  von Hippel-Lindau disease: a clinical and scientific review.

Authors:  Eamonn R Maher; Hartmut Ph Neumann; Stéphane Richard
Journal:  Eur J Hum Genet       Date:  2011-03-09       Impact factor: 4.246

4.  Identification of the von Hippel-Lindau disease tumor suppressor gene.

Authors:  F Latif; K Tory; J Gnarra; M Yao; F M Duh; M L Orcutt; T Stackhouse; I Kuzmin; W Modi; L Geil
Journal:  Science       Date:  1993-05-28       Impact factor: 47.728

5.  The UF family of reference hybrid phantoms for computational radiation dosimetry.

Authors:  Choonsik Lee; Daniel Lodwick; Jorge Hurtado; Deanna Pafundi; Jonathan L Williams; Wesley E Bolch
Journal:  Phys Med Biol       Date:  2009-12-17       Impact factor: 3.609

Review 6.  Imaging features of von Hippel-Lindau disease.

Authors:  Rebecca S Leung; Sona V Biswas; Mark Duncan; Sheila Rankin
Journal:  Radiographics       Date:  2008 Jan-Feb       Impact factor: 5.333

Review 7.  von Hippel-Lindau disease.

Authors:  Russell R Lonser; Gladys M Glenn; McClellan Walther; Emily Y Chew; Steven K Libutti; W Marston Linehan; Edward H Oldfield
Journal:  Lancet       Date:  2003-06-14       Impact factor: 79.321

8.  NCICT: a computational solution to estimate organ doses for pediatric and adult patients undergoing CT scans.

Authors:  Choonsik Lee; Kwang Pyo Kim; Wesley E Bolch; Brian E Moroz; Les Folio
Journal:  J Radiol Prot       Date:  2015-11-26       Impact factor: 1.394

9.  Calculating optimal surveillance for detection of von Hippel-Lindau-related manifestations.

Authors:  Roeliene C Kruizinga; Wim J Sluiter; Elisabeth G E de Vries; Bernard A Zonnenberg; Cornelis J Lips; Anouk N A van der Horst-Schrivers; Annemiek M E Walenkamp; Thera P Links
Journal:  Endocr Relat Cancer       Date:  2013-12-20       Impact factor: 5.678

Review 10.  Evaluation and management of pancreatic lesions in patients with von Hippel-Lindau disease.

Authors:  Xavier M Keutgen; Pascal Hammel; Peter L Choyke; Steven K Libutti; Eric Jonasch; Electron Kebebew
Journal:  Nat Rev Clin Oncol       Date:  2016-03-31       Impact factor: 66.675

View more
  1 in total

Review 1.  Phakomatoses and Endocrine Gland Tumors: Noteworthy and (Not so) Rare Associations.

Authors:  Benjamin Chevalier; Hippolyte Dupuis; Arnaud Jannin; Madleen Lemaitre; Christine Do Cao; Catherine Cardot-Bauters; Stéphanie Espiard; Marie Christine Vantyghem
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-06       Impact factor: 5.555

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.